Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Shares of Bicycle Therapeutics PLC Sponsored ADR (NASDAQ:BCYC) have earned an average rating of “Moderate Buy” from the twelve analysts that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $21.1111.

A number of equities analysts recently issued reports on BCYC shares. Citigroup reissued an “outperform” rating on shares of Bicycle Therapeutics in a report on Friday, October 31st. Truist Financial started coverage on shares of Bicycle Therapeutics in a research note on Monday, November 24th. They set a “hold” rating and a $10.00 price target on the stock. Jefferies Financial Group upgraded Bicycle Therapeutics to a “strong-buy” rating in a research note on Tuesday. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $11.00 target price (down from $27.00) on shares of Bicycle Therapeutics in a report on Friday, October 31st. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Bicycle Therapeutics in a report on Monday, December 22nd.

Bicycle Therapeutics Price Performance

BCYC stock opened at $5.38 on Friday. Bicycle Therapeutics has a 1 year low of $5.03 and a 1 year high of $12.60. The company has a market cap of $373.21 million, a P/E ratio of -1.49 and a beta of 1.63. The stock’s fifty day moving average price is $6.52 and its 200-day moving average price is $7.07.

Insider Buying and Selling

In related news, CFO Alethia Young sold 4,334 shares of the stock in a transaction that occurred on Monday, January 5th. The shares were sold at an average price of $6.49, for a total value of $28,127.66. Following the completion of the sale, the chief financial officer directly owned 87,081 shares of the company’s stock, valued at approximately $565,155.69. This represents a 4.74% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Kevin Lee sold 10,989 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was sold at an average price of $6.46, for a total transaction of $70,988.94. Following the completion of the transaction, the chief executive officer owned 618,996 shares of the company’s stock, valued at approximately $3,998,714.16. The trade was a 1.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 38,029 shares of company stock valued at $251,966. 22.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Bicycle Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Principal Financial Group Inc. grew its stake in Bicycle Therapeutics by 64.7% during the third quarter. Principal Financial Group Inc. now owns 1,148,402 shares of the company’s stock valued at $8,889,000 after acquiring an additional 451,135 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Bicycle Therapeutics during the 2nd quarter valued at about $320,000. Acadian Asset Management LLC grew its position in shares of Bicycle Therapeutics by 454.1% during the second quarter. Acadian Asset Management LLC now owns 698,501 shares of the company’s stock valued at $4,840,000 after purchasing an additional 572,439 shares in the last quarter. Jefferies Financial Group Inc. increased its holdings in shares of Bicycle Therapeutics by 12.8% in the second quarter. Jefferies Financial Group Inc. now owns 461,100 shares of the company’s stock worth $3,205,000 after purchasing an additional 52,211 shares during the last quarter. Finally, Tybourne Capital Management HK Ltd. lifted its position in shares of Bicycle Therapeutics by 72.4% in the second quarter. Tybourne Capital Management HK Ltd. now owns 993,743 shares of the company’s stock worth $6,907,000 after buying an additional 417,400 shares in the last quarter. 86.15% of the stock is owned by institutional investors.

About Bicycle Therapeutics

Bicycle Therapeutics plc is a clinical-stage biotechnology company specializing in the discovery and development of novel peptide therapeutics based on its proprietary bicyclic peptide platform. The company’s core technology leverages constrained peptide structures that combine the binding specificity of biologics with the favorable tissue-penetration properties of small molecules. This approach is designed to generate highly selective drug candidates with potential applications across a range of therapeutic areas, including oncology, neuroscience and immunology.

Bicycle Therapeutics maintains a diversified pipeline of internally developed programs as well as collaborations with leading pharmaceutical partners.